Govt expands central licensing rules to cover gene and stem cell therapies
New Delhi, July 2
The Central Government has amended the Drugs Rules, 1945 to bring cell or stem cell derived products, gene therapeutic products and xenografts under the Centrally License Approving Authority framework, a statement said on Thursday, adding that the move strengthens the regulatory oversight of advanced and emerging medical technologies.
The move expands the set of critical drugs and biological products that receive joint regulatory supervision by central and state authorities under the Drugs and Cosmetics Act, which already covers vaccines, large‑volume parenterals and r‑DNA based medicines.
Through the new amendment the government expanded the Centrally License Approving Authority (CLAA) Framework to include Cell and Stem Cell-derived Products, gene therapeutics and xenografts.
The amendment aims to ensure uniformity in regulatory standards nationwide for rapidly evolving medical technologies, the statement from the Ministry of Health and Family Welfare said.
The amendment will increase regulatory rigour for emerging technologies and reinforcing India's regulatory framework in line with scientific advancements and global best practices, the ministry said.
Cell or Stem Cell derived products e.g. such as stem cell-based regenerative treatments, CAR-T cell therapies have seen increasing use in treatment of blood cancers such as leukemias and lymphomas.
Gene therapeutic products such as gene replacement and gene editing products are used in treating genetic disorders and various types of cancers. Xenografts are animal tissue-derived products such as heart valves which can be transplanted into humans used in cardiology and orthopedics.
As these technologies represent highly complex, specialized and rapidly evolving areas of medical science, they need enhanced regulatory scrutiny to ensure patient safety, the ministry said.
"This initiative reflects the government's continued commitment towards safeguarding public health while promoting innovation and quicker adoption of latest technologies in healthcare and life sciences sectors," the statement noted.
— IANS
Reader Comments
This is a double-edged sword. On one hand, regulation is needed to prevent exploitation. On the other hand, India's drug regulatory system is already slow and bureaucratic—will this delay access to cutting-edge treatments for patients who need them? Many cancer patients can't afford to wait years for approvals. Hope the implementation is quick and efficient.
As someone working in biotech in Bangalore, this is a welcome step. India needs to align with global regulatory standards like the EMA and FDA if we want to be a hub for cell and gene therapy manufacturing. The current patchwork of state-level approvals was chaotic. This centralization should bring consistency and attract more investment.
Good initiative but the real challenge will be enforcement. We have so many good laws on paper that don't actually get implemented properly. Also, this will increase costs for small biotech startups—hope there's some support for Indian innovators. Still, better late than never. 🙏
Interesting development. I've seen how loose regulation led to medical tourism disasters in other countries. India has a huge potential in regenerative medicine but needs strong oversight. The mention of xenografts is particularly important—animal-to-human transplants require careful monitoring for ethical and safety reasons.
As a doctor, I welcome this. We've seen too many patients with complications from unregulated stem cell injections. CAR-T therapy is a game-changer for blood cancers but it's also high-risk. Central oversight means standardized protocols and better adverse event reporting. The MOHFW is doing the right thing.
We welcome thoughtful discussions from our readers. Please keep comments respectful and on-topic.